[1] Wilson A, Cohen J.Patient access to new cancer drugs in the United States and Australia[J]. Value in Health, 2011, 14(6): 944-952. [2] Kantarjian HM, Fojo T, Mathisen M, et al.Cancer drugs in the United States: Justum Pretium—the just price[J]. Journal of Clinical Oncology, 2013, 31(28): 3600. [3] Robinson JC, Howell S.Specialty pharmaceuticals: policy initiatives to improve assessment, pricing, prescription, and use[J]. Health Affairs, 2014, 33(10): 1745-1750. [4] Cunningham PJ.The share of people with high medical costs increased prior to implementation of the affordable care act[J]. Health Affairs, 2015, 34(1): 117-124. [5] Doshi JA, Li P, Pettit AR, et al.Association of patient out-of-pocket costs with prescription abandonment and delay in fills of novel oral anticancer agents[J]. J Clin Oncol, 2018, 36(5): 476-482. [6] Carrera PM, Kantarjian HM, Blinder VS.The financial burden and distress of patients with cancer: understanding and stepping-up action on the financial toxicity of cancer treatment[J]. CA Cancer J Clin, 2018, 68(2): 153-165. [7] Chen XZ, Jiang K, Hu JK, et al.Cost-effectiveness analysis of chemotherapy for advanced gastric cancer in China[J]. World Journal of Gastroenterology, 2008, 14(17):2715-2722. [8] Crathorne L, Huxley N, Haasova M, et al.The effectiveness and cost-effectiveness of erythropoiesis-stimulating agents (epoetin and darbepoetin) for treating cancer treatment-induced anaemia (including review of technology appraisal no. 142): a systematic review and economic model[J]. Health Technol Assess, 2016, 20(13): 1-588. [9] Lazzaro C, Barone C, Caprioni F, et al.An Italian cost-effectiveness analysis of paclitaxel albumin (nab-paclitaxel) + gemcitabine vs gemcitabine alone for metastatic pancreatic cancer patients: the APICE study[J]. Expert Rev Pharmacoecon Outcomes Res, 2018, 18(4): 435-446. [10] Hirsh V, Singh J.Optimal sequencing strategies in the treatment of EGFR mutation-positive non-small cell lung cancer: clinical benefits and cost-effectiveness[J]. Am J Health Syst Pharm, 2020, 77(18): 1466-1476. [11] Maximiano S, Magalhães P, Guerreiro MP, et al.Trastuzumab in the treatment of breast cancer[J]. Bio Drugs, 2016, 30(2): 75-86. [12] Mármol I, Sánchez-de-Diego C, Pradilla DA, et al. Colore-ctal carcinoma: a general overview and future perspectives in colorectal cancer[J]. Int J Mol Sci, 2017, 18(1): 197. [13] Van Cutsem E, Köhne CH, Hitre E, et al.Cetuximab and chemot-herapy as initial treatment for metastatic colorectal cancer[J]. N Engl J Med, 2009, 360(14): 1408-1417. [14] Yoneda K, Imanishi N, Ichiki Y, et al.Treatment of non-small cell lung cancer with EGFR-mutations[J]. J Uoeh, 2019, 41(2): 153-163. [15] Ahn MJ, Sun JM, Lee SH, et al.Egfr tki combination with immunotherapy in non-small cell lung cancer[J]. Expert Opin Drug Saf, 2017, 16(4): 465-469. [16] HHerbst RS, Garon EB, Kim DW, et al.Long-term outcomes and retreatment among patients with previously treated, programmed death-ligand 1-positive, advanced non-small-cell lung cancer in the KEYNOTE-010 study[J]. Clin Oncol, 2020, 38(14): 1580-1590. |